TG THERAPEUTICS, INC. Revenues
TG THERAPEUTICS, INC. (TGTX) reported Revenues of $2.79 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2023-03-01
- TG THERAPEUTICS, INC. revenues for the quarter ending 2022-12-31 was $80.00K, a 96.55% decline year-over-year.
- TG THERAPEUTICS, INC. revenues for the quarter ending 2022-09-30 was $94.00K, a 95.37% decline year-over-year.
- TG THERAPEUTICS, INC. revenues for the quarter ending 2022-06-30 was $594.00K, a 61.55% decline year-over-year.
- TG THERAPEUTICS, INC. revenues for the quarter ending 2022-03-31 was $2.02M, a 154.22% increase year-over-year.
- TG THERAPEUTICS, INC. revenues for fiscal 2022 was $2.79M, a 58.36% decline from fiscal 2021.
- TG THERAPEUTICS, INC. revenues for fiscal 2021 was $6.69M, a 4300.66% increase from fiscal 2020.
- TG THERAPEUTICS, INC. revenues for fiscal 2020 was $152.00K, a 0.00% change from fiscal 2019.
- TG THERAPEUTICS, INC. revenues for fiscal 2019 was $152.00K, a 0.00% change from fiscal 2018.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2022-12-31 | $80.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $174.00K derived: sum of 2 quarters · filed 2023-03-01 | $768.00K derived: sum of 3 quarters · filed 2023-03-01 | $2.79M 10-K · filed 2023-03-01 |
| 2022-09-30 | $94.00K 10-Q · filed 2022-11-09 | $688.00K derived: sum of 2 quarters · filed 2022-11-09 | $2.71M 10-Q · filed 2022-11-09 | $5.03M derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-06-30 | $594.00K 10-Q · filed 2022-08-09 | $2.61M 10-Q · filed 2022-08-09 | $4.93M derived: sum of 3 quarters · filed 2023-03-01 | $6.96M derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-03-31 | $2.02M 10-Q · filed 2022-05-10 | $4.34M derived: sum of 2 quarters · filed 2023-03-01 | $6.37M derived: sum of 3 quarters · filed 2023-03-01 | $7.91M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.35M derived: sum of 2 quarters · filed 2023-03-01 | $5.90M derived: sum of 3 quarters · filed 2023-03-01 | $6.69M 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.03M 10-Q · filed 2022-11-09 | $3.58M derived: sum of 2 quarters · filed 2022-11-09 | $4.37M 10-Q · filed 2022-11-09 | $4.41M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.54M 10-Q · filed 2022-08-09 | $2.34M 10-Q · filed 2022-08-09 | $2.38M derived: sum of 3 quarters · filed 2023-03-01 | $2.41M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $793.00K 10-Q · filed 2022-05-10 | $831.00K derived: sum of 2 quarters · filed 2023-03-01 | $869.00K derived: sum of 3 quarters · filed 2023-03-01 | $907.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $76.00K derived: sum of 2 quarters · filed 2023-03-01 | $114.00K derived: sum of 3 quarters · filed 2023-03-01 | $152.00K 10-K · filed 2023-03-01 |
| 2020-09-30 | $38.00K 10-Q · filed 2021-11-08 | $76.00K derived: sum of 2 quarters · filed 2021-11-08 | $114.00K 10-Q · filed 2021-11-08 | $152.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $38.00K 10-Q · filed 2021-08-06 | $76.00K 10-Q · filed 2021-08-06 | $114.00K derived: sum of 3 quarters · filed 2022-03-01 | $152.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $38.00K 10-Q · filed 2021-05-10 | $76.00K derived: sum of 2 quarters · filed 2022-03-01 | $114.00K derived: sum of 3 quarters · filed 2022-03-01 | $152.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $76.00K derived: sum of 2 quarters · filed 2022-03-01 | $114.00K derived: sum of 3 quarters · filed 2022-03-01 | $152.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $38.00K 10-Q · filed 2020-11-09 | $76.00K derived: sum of 2 quarters · filed 2020-11-09 | $114.00K 10-Q · filed 2020-11-09 | $152.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $38.00K 10-Q · filed 2020-08-10 | $76.00K 10-Q · filed 2020-08-10 | $114.00K derived: sum of 3 quarters · filed 2021-03-01 | $152.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $38.00K 10-Q · filed 2020-05-11 | $76.00K derived: sum of 2 quarters · filed 2021-03-01 | $114.00K derived: sum of 3 quarters · filed 2021-03-01 | $152.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $76.00K derived: sum of 2 quarters · filed 2021-03-01 | $114.00K derived: sum of 3 quarters · filed 2021-03-01 | $152.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $38.00K 10-Q · filed 2019-11-12 | $76.00K derived: sum of 2 quarters · filed 2019-11-12 | $114.00K 10-Q · filed 2019-11-12 | $152.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $38.00K 10-Q · filed 2019-08-09 | $76.00K 10-Q · filed 2019-08-09 | $114.00K derived: sum of 3 quarters · filed 2020-03-02 | $152.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $38.00K 10-Q · filed 2019-05-10 | $76.00K derived: sum of 2 quarters · filed 2020-03-02 | $114.00K derived: sum of 3 quarters · filed 2020-03-02 | $152.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $76.00K derived: sum of 2 quarters · filed 2020-03-02 | $114.00K derived: sum of 3 quarters · filed 2020-03-02 | $152.00K 10-K · filed 2020-03-02 |
| 2017-09-30 | $38.00K 10-Q · filed 2018-11-09 | $76.00K derived: sum of 2 quarters · filed 2018-11-09 | $114.00K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $38.00K 10-Q · filed 2018-08-09 | $76.00K 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $152.00K 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |